Compugen (CGEN) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- Wall St set for subdued open on final trading day of strong quarter
- Strong dollar pushes yen to 40-year low as traders test Japanese authorities
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Logitech dips as BofA downgrades stock on demand outlook concerns
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
Compugen Reports First Quarter 2022 Results
May 16, 2022 7:00 AM EDTTriple blockade of PVRIG/TIGIT/PD-1 may be required to optimize clinical responsesCOM701, a unique check point inhibitor, with potential to recruit additional T cells to the TMECOM902 has the potential to be a best-in-class anti-TIGIT antibodyOn track to deliver clinical data from the cohort expansion study of COM701/nivolumab in MSS CRC in Q4 2022Enrollment continues in the Phase 1 clinical studies for COM701 and COM902Cash balance of $107 million affirms focus on capital efficiency with bold execution on Compugen's DNAM-1 axis... More
